Targeting RUNX3 as a novel treatment for hemophagocytic lymphohistiocytosis
Active Grant Awarded
- Award ID
- R21AI202573
- Recipient
-
The University Of Texas Health Science Center At Tyler UEI FPCUDWBE7DX2 Part of University Of Texas System
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $223,500
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 17% complete
- Place of performance
- Tyler, TX 75708, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, through the National Institutes of Health's National Institute of Allergy and Infectious Diseases, awarded $223,500 to The University of Texas Health Science Center at Tyler on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds grant R21AI202573, an R21 research project that tests RUNX3, a critical regulator of CD8+ T cells, as a novel treatment for primary hemophagocytic lymphohistiocytosis (PHLH), a life-threatening inborn error of immunity. The project builds on prior findings that RUNX3 is essential for CD8+ cytotoxic T cell activation and expansion during lymphocytic choriomeningitis virus and influenza A infection, and on new preliminary data showing RUNX3 preferentially mediates interferon production from T cells, especially CD8+ T cells, in response to IL-12 plus IL-18. The period of performance runs from the July 20, 2026 award date through an ultimate completion date of June 30, 2028. Place of performance is Tyler, Texas 75708. The program supports public and private nonprofit institutions in establishing, expanding, and improving biomedical research and research training in infectious diseases and related areas, including developmental research.
Description
- Abstract
- Primary hemophagocytic lymphohistiocytosis (PHLH) is a life-threatening genetic disease (inborn error of immunity) caused by biallelic mutations in genes involved in the cytotoxic machinery of cytotoxic CD8+ T and NK cells. When triggered by a viral infection, the impaired cytotoxic functions result in the exuberant activation and expansion of IFN-producing CD8+ T cells, leading to a self-perpetuating IFN-driven cytokine storm and hemophagocytosis. PHLH commonly occurs in early childhood and is often triggered by viral infection, although pathogens are diverse (viral, bacterial and fungal) and influenced by geographic regions. Despite use of the conventional immunosuppressive and chemotherapeutic regimens and the recently developed anti-IFN therapies, up to 40% of PHLH patients DIE due to uncontrolled disease and/or the complications of its treatment. Hence, there is a pressing need to develop novel and more effective therapies with less toxicity to ultimately improve outcomes for PHLH patients. This R21 proposal will address this important issue by targeting RUNX3 (a critical regulator of CD8+ T cells) for the treatment of PHLH. We and other groups have demonstrated that RUNX3 is essential for the activation and expansion of CD8+ cytotoxic T cells and the cell expression of IFN in response to the infections of lymphocytic choriomeningitis virus (LCMV) or influenza a virus (IAV). We also found that an inducible general RUNX3 KO did not significantly alter IAV clearance in mice but tended to improve animal survival outcomes following IAV infection, although the numbers of lung CD8+ cytotoxic T cells were markedly reduced. Our new preliminary data show that RUNX3 preferentially mediates IFN production from T cells, especially CD8+ T cells by IL-12 plus IL-18 that are two potent inducers of IFN production. Moreover, RUNX3 regulates IL-12/IL- 18-mediated production of IFN in mice with endotoxin lipopolysaccharide (LPS) challenge. As a result, RUNX3 KO markedly suppressed the IFN-central cytokine storm and mortality in mice challenged with a lethal dose of LPS. These preliminary data prompt US to test the hypothesis that targeting RUNX3 could be an effective therapeutic strategy for PHLH. We will test this novel hypothesis with the following two sub-aims. 1) determine the role of RUNX3 in PHLH using a LCMV-infected PRF1−/−; RUNX3-KO mouse model; 2) determine the effect of RUNX3 KO after the onset of PHLH on host immune responses. The proposed studies have not been explored previously and will offer proof of concept that targeting RUNX3 is a tolerable and effective therapeutic strategy for PHLH, a life-threatening hyperinflammatory disease, thereby will advance the field. If successful, this proposal will attract future development of RUNX3 selective inhibitors to treat this often-fatal HLH disease.
Quick answers
Who received award R21AI202573?
R21AI202573 was awarded to The University Of Texas Health Science Center At Tyler by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 20, 2026.
How much is award R21AI202573 worth?
$223,500 has been obligated on R21AI202573.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award